UCB SA
UCB SA UCB.BR Peers
See (UCB.BR) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UCB.BR | €162.75 | +0.03% | 30.9B | 30.31 | €5.37 | +0.85% |
| ARGX.BR | €516.20 | +1.06% | 31.5B | 35.77 | €14.43 | N/A |
| TUB.BR | €130.20 | +0.77% | 5.8B | 64.46 | €2.02 | +0.80% |
| GLPG.AS | €24.86 | +0.89% | 1.6B | -9.11 | -€2.73 | N/A |
| PHARM.AS | €1.04 | +3.17% | 709.6M | -52.15 | -€0.02 | N/A |
| GTBP.PA | €280.50 | N/A | 626.7M | -4.10 | -€68.39 | N/A |
| MEDCL.PA | €16.14 | -1.04% | 533.7M | -14.81 | -€1.09 | N/A |
| ABVX.PA | €7.36 | +4.99% | 466.9M | -2.49 | -€2.95 | N/A |
| VLA.PA | €2.72 | -2.02% | 461.9M | -4.85 | -€0.56 | N/A |
| IVA.PA | €3.02 | +3.97% | 419.4M | -0.98 | -€3.08 | N/A |
Stock Comparison
UCB.BR vs ARGX.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ARGX.BR has a market cap of 31.5B. Regarding current trading prices, UCB.BR is priced at €162.75, while ARGX.BR trades at €516.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ARGX.BR's P/E ratio is 35.77. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ARGX.BR's ROE of +0.17%. Regarding short-term risk, UCB.BR is less volatile compared to ARGX.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs TUB.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, TUB.BR has a market cap of 5.8B. Regarding current trading prices, UCB.BR is priced at €162.75, while TUB.BR trades at €130.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas TUB.BR's P/E ratio is 64.46. In terms of profitability, UCB.BR's ROE is +0.11%, compared to TUB.BR's ROE of +0.05%. Regarding short-term risk, UCB.BR is more volatile compared to TUB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs GLPG.AS Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, GLPG.AS has a market cap of 1.6B. Regarding current trading prices, UCB.BR is priced at €162.75, while GLPG.AS trades at €24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas GLPG.AS's P/E ratio is -9.11. In terms of profitability, UCB.BR's ROE is +0.11%, compared to GLPG.AS's ROE of -0.06%. Regarding short-term risk, UCB.BR is less volatile compared to GLPG.AS. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs PHARM.AS Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, PHARM.AS has a market cap of 709.6M. Regarding current trading prices, UCB.BR is priced at €162.75, while PHARM.AS trades at €1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas PHARM.AS's P/E ratio is -52.15. In terms of profitability, UCB.BR's ROE is +0.11%, compared to PHARM.AS's ROE of -0.06%. Regarding short-term risk, UCB.BR is less volatile compared to PHARM.AS. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs GTBP.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, GTBP.PA has a market cap of 626.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while GTBP.PA trades at €280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas GTBP.PA's P/E ratio is -4.10. In terms of profitability, UCB.BR's ROE is +0.11%, compared to GTBP.PA's ROE of -4.68%. Regarding short-term risk, UCB.BR is less volatile compared to GTBP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs MEDCL.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, MEDCL.PA has a market cap of 533.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while MEDCL.PA trades at €16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas MEDCL.PA's P/E ratio is -14.81. In terms of profitability, UCB.BR's ROE is +0.11%, compared to MEDCL.PA's ROE of +0.66%. Regarding short-term risk, UCB.BR is less volatile compared to MEDCL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ABVX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ABVX.PA has a market cap of 466.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ABVX.PA trades at €7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ABVX.PA's P/E ratio is -2.49. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ABVX.PA's ROE of -2.11%. Regarding short-term risk, UCB.BR is less volatile compared to ABVX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs VLA.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, VLA.PA has a market cap of 461.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while VLA.PA trades at €2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas VLA.PA's P/E ratio is -4.85. In terms of profitability, UCB.BR's ROE is +0.11%, compared to VLA.PA's ROE of -0.43%. Regarding short-term risk, UCB.BR is less volatile compared to VLA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs IVA.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, IVA.PA has a market cap of 419.4M. Regarding current trading prices, UCB.BR is priced at €162.75, while IVA.PA trades at €3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas IVA.PA's P/E ratio is -0.98. In terms of profitability, UCB.BR's ROE is +0.11%, compared to IVA.PA's ROE of +1.98%. Regarding short-term risk, UCB.BR is less volatile compared to IVA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ORY.MC Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ORY.MC has a market cap of 220M. Regarding current trading prices, UCB.BR is priced at €162.75, while ORY.MC trades at €2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ORY.MC's P/E ratio is -47.33. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ORY.MC's ROE of -0.04%. Regarding short-term risk, UCB.BR is less volatile compared to ORY.MC. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs DBV.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, DBV.PA has a market cap of 203.4M. Regarding current trading prices, UCB.BR is priced at €162.75, while DBV.PA trades at €1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas DBV.PA's P/E ratio is -1.47. In terms of profitability, UCB.BR's ROE is +0.11%, compared to DBV.PA's ROE of -2.68%. Regarding short-term risk, UCB.BR is less volatile compared to DBV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs NANO.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, NANO.PA has a market cap of 195.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while NANO.PA trades at €4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas NANO.PA's P/E ratio is -2.89. In terms of profitability, UCB.BR's ROE is +0.11%, compared to NANO.PA's ROE of +0.77%. Regarding short-term risk, UCB.BR is less volatile compared to NANO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ONWD.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ONWD.BR has a market cap of 190.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ONWD.BR trades at €4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ONWD.BR's P/E ratio is -5.34. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ONWD.BR's ROE of -1.08%. Regarding short-term risk, UCB.BR is less volatile compared to ONWD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs GNFT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, GNFT.PA has a market cap of 185.3M. Regarding current trading prices, UCB.BR is priced at €162.75, while GNFT.PA trades at €3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas GNFT.PA's P/E ratio is 124.07. In terms of profitability, UCB.BR's ROE is +0.11%, compared to GNFT.PA's ROE of +0.02%. Regarding short-term risk, UCB.BR is less volatile compared to GNFT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs IPH.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, IPH.PA has a market cap of 176.6M. Regarding current trading prices, UCB.BR is priced at €162.75, while IPH.PA trades at €1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas IPH.PA's P/E ratio is -3.14. In terms of profitability, UCB.BR's ROE is +0.11%, compared to IPH.PA's ROE of -2.63%. Regarding short-term risk, UCB.BR is more volatile compared to IPH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs HYL.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, HYL.BR has a market cap of 171.4M. Regarding current trading prices, UCB.BR is priced at €162.75, while HYL.BR trades at €6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas HYL.BR's P/E ratio is -26.61. In terms of profitability, UCB.BR's ROE is +0.11%, compared to HYL.BR's ROE of -0.19%. Regarding short-term risk, UCB.BR is less volatile compared to HYL.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs OSE.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, OSE.PA has a market cap of 131.4M. Regarding current trading prices, UCB.BR is priced at €162.75, while OSE.PA trades at €5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas OSE.PA's P/E ratio is 4.03. In terms of profitability, UCB.BR's ROE is +0.11%, compared to OSE.PA's ROE of +0.52%. Regarding short-term risk, UCB.BR is less volatile compared to OSE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs TNG.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, TNG.PA has a market cap of 124.8M. Regarding current trading prices, UCB.BR is priced at €162.75, while TNG.PA trades at €0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas TNG.PA's P/E ratio is -3.26. In terms of profitability, UCB.BR's ROE is +0.11%, compared to TNG.PA's ROE of -4.66%. Regarding short-term risk, UCB.BR is less volatile compared to TNG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALSEN.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALSEN.PA has a market cap of 123.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALSEN.PA trades at €0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALSEN.PA's P/E ratio is -4.56. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALSEN.PA's ROE of -0.33%. Regarding short-term risk, UCB.BR is less volatile compared to ALSEN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALCLS.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALCLS.PA has a market cap of 92.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALCLS.PA trades at €1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALCLS.PA's P/E ratio is -2.22. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALCLS.PA's ROE of -0.29%. Regarding short-term risk, UCB.BR is less volatile compared to ALCLS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs MAAT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, MAAT.PA has a market cap of 82.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while MAAT.PA trades at €5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas MAAT.PA's P/E ratio is -2.50. In terms of profitability, UCB.BR's ROE is +0.11%, compared to MAAT.PA's ROE of -1.61%. Regarding short-term risk, UCB.BR is less volatile compared to MAAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ADOC.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ADOC.PA has a market cap of 62.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while ADOC.PA trades at €3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ADOC.PA's P/E ratio is -3.47. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ADOC.PA's ROE of +1.28%. Regarding short-term risk, UCB.BR is less volatile compared to ADOC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ERYP.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ERYP.PA has a market cap of 48.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while ERYP.PA trades at €0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ERYP.PA's P/E ratio is -80.10. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ERYP.PA's ROE of -0.73%. Regarding short-term risk, UCB.BR is less volatile compared to ERYP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs VVY.AS Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, VVY.AS has a market cap of 44.8M. Regarding current trading prices, UCB.BR is priced at €162.75, while VVY.AS trades at €1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas VVY.AS's P/E ratio is -2.18. In terms of profitability, UCB.BR's ROE is +0.11%, compared to VVY.AS's ROE of -1.88%. Regarding short-term risk, UCB.BR is less volatile compared to VVY.AS. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ABNX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ABNX.PA has a market cap of 44.3M. Regarding current trading prices, UCB.BR is priced at €162.75, while ABNX.PA trades at €1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ABNX.PA's P/E ratio is -9.83. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ABNX.PA's ROE of -0.52%. Regarding short-term risk, UCB.BR is more volatile compared to ABNX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs POXEL.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, POXEL.PA has a market cap of 39.5M. Regarding current trading prices, UCB.BR is priced at €162.75, while POXEL.PA trades at €0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas POXEL.PA's P/E ratio is -1.64. In terms of profitability, UCB.BR's ROE is +0.11%, compared to POXEL.PA's ROE of +0.32%. Regarding short-term risk, UCB.BR is less volatile compared to POXEL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALGEN.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALGEN.PA has a market cap of 31.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALGEN.PA trades at €3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALGEN.PA's P/E ratio is 13.64. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALGEN.PA's ROE of +0.10%. Regarding short-term risk, UCB.BR is less volatile compared to ALGEN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs COX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, COX.PA has a market cap of 29M. Regarding current trading prices, UCB.BR is priced at €162.75, while COX.PA trades at €0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas COX.PA's P/E ratio is -0.46. In terms of profitability, UCB.BR's ROE is +0.11%, compared to COX.PA's ROE of -0.43%. Regarding short-term risk, UCB.BR is less volatile compared to COX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs SIGHT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, SIGHT.PA has a market cap of 26.1M. Regarding current trading prices, UCB.BR is priced at €162.75, while SIGHT.PA trades at €0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas SIGHT.PA's P/E ratio is -1.34. In terms of profitability, UCB.BR's ROE is +0.11%, compared to SIGHT.PA's ROE of +0.54%. Regarding short-term risk, UCB.BR is less volatile compared to SIGHT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs FALG.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, FALG.PA has a market cap of 24M. Regarding current trading prices, UCB.BR is priced at €162.75, while FALG.PA trades at €0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas FALG.PA's P/E ratio is -2.33. In terms of profitability, UCB.BR's ROE is +0.11%, compared to FALG.PA's ROE of -0.39%. Regarding short-term risk, UCB.BR is less volatile compared to FALG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs DMSIM.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, DMSIM.BR has a market cap of 23.1M. Regarding current trading prices, UCB.BR is priced at €162.75, while DMSIM.BR trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas DMSIM.BR's P/E ratio is 0.09. In terms of profitability, UCB.BR's ROE is +0.11%, compared to DMSIM.BR's ROE of -0.57%. Regarding short-term risk, UCB.BR is less volatile compared to DMSIM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALDVI.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALDVI.PA has a market cap of 21.5M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALDVI.PA trades at €1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALDVI.PA's P/E ratio is -3.66. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALDVI.PA's ROE of +0.44%. Regarding short-term risk, UCB.BR is more volatile compared to ALDVI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs CYAD.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, CYAD.BR has a market cap of 16.6M. Regarding current trading prices, UCB.BR is priced at €162.75, while CYAD.BR trades at €0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas CYAD.BR's P/E ratio is -0.29. In terms of profitability, UCB.BR's ROE is +0.11%, compared to CYAD.BR's ROE of +0.91%. Regarding short-term risk, UCB.BR is less volatile compared to CYAD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs AELIS.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, AELIS.PA has a market cap of 16.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while AELIS.PA trades at €1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas AELIS.PA's P/E ratio is -2.15. In terms of profitability, UCB.BR's ROE is +0.11%, compared to AELIS.PA's ROE of -0.74%. Regarding short-term risk, UCB.BR is less volatile compared to AELIS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALPHE.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALPHE.PA has a market cap of 15.8M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALPHE.PA trades at €2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALPHE.PA's P/E ratio is -2.67. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALPHE.PA's ROE of -0.64%. Regarding short-term risk, UCB.BR is less volatile compared to ALPHE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALNFL.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALNFL.PA has a market cap of 14.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALNFL.PA trades at €1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALNFL.PA's P/E ratio is -5.56. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALNFL.PA's ROE of -1.27%. Regarding short-term risk, UCB.BR is less volatile compared to ALNFL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALVAL.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALVAL.PA has a market cap of 14.5M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALVAL.PA trades at €0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALVAL.PA's P/E ratio is -1.44. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALVAL.PA's ROE of -0.74%. Regarding short-term risk, UCB.BR is less volatile compared to ALVAL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALPAT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALPAT.PA has a market cap of 11.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALPAT.PA trades at €10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALPAT.PA's P/E ratio is 12.59. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALPAT.PA's ROE of +0.01%. Regarding short-term risk, UCB.BR is less volatile compared to ALPAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs BAI.AS Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, BAI.AS has a market cap of 11.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while BAI.AS trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas BAI.AS's P/E ratio is -0.13. In terms of profitability, UCB.BR's ROE is +0.11%, compared to BAI.AS's ROE of -0.51%. Regarding short-term risk, UCB.BR is less volatile compared to BAI.AS. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALVIO.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALVIO.PA has a market cap of 10.1M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALVIO.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALVIO.PA's P/E ratio is -0.47. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALVIO.PA's ROE of -2.09%. Regarding short-term risk, UCB.BR is less volatile compared to ALVIO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALVET.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALVET.PA has a market cap of 10M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALVET.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALVET.PA's P/E ratio is -0.17. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALVET.PA's ROE of -0.32%. Regarding short-term risk, UCB.BR is less volatile compared to ALVET.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs APM.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, APM.PA has a market cap of 8.8M. Regarding current trading prices, UCB.BR is priced at €162.75, while APM.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas APM.PA's P/E ratio is -0.71. In terms of profitability, UCB.BR's ROE is +0.11%, compared to APM.PA's ROE of +0.08%. Regarding short-term risk, UCB.BR is less volatile compared to APM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALTME.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALTME.PA has a market cap of 7.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALTME.PA trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALTME.PA's P/E ratio is -0.72. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALTME.PA's ROE of -8.99%. Regarding short-term risk, UCB.BR is less volatile compared to ALTME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALTHX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALTHX.PA has a market cap of 7.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALTHX.PA trades at €0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALTHX.PA's P/E ratio is -4.09. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALTHX.PA's ROE of +7.08%. Regarding short-term risk, UCB.BR is less volatile compared to ALTHX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALQGC.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALQGC.PA has a market cap of 5M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALQGC.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALQGC.PA's P/E ratio is -0.09. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALQGC.PA's ROE of +14.01%. Regarding short-term risk, UCB.BR is less volatile compared to ALQGC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs LYS.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, LYS.PA has a market cap of 4.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while LYS.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas LYS.PA's P/E ratio is -0.64. In terms of profitability, UCB.BR's ROE is +0.11%, compared to LYS.PA's ROE of -11.30%. Regarding short-term risk, UCB.BR is more volatile compared to LYS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALHYG.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALHYG.PA has a market cap of 3.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALHYG.PA trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALHYG.PA's P/E ratio is -0.26. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALHYG.PA's ROE of -6.80%. Regarding short-term risk, UCB.BR is less volatile compared to ALHYG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALACT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALACT.PA has a market cap of 3.9M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALACT.PA trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALACT.PA's P/E ratio is -0.22. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALACT.PA's ROE of +1.38%. Regarding short-term risk, UCB.BR is less volatile compared to ALACT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALINT.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALINT.PA has a market cap of 3.5M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALINT.PA trades at €0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALINT.PA's P/E ratio is -13.05. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALINT.PA's ROE of -0.14%. Regarding short-term risk, UCB.BR is more volatile compared to ALINT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALBPS.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALBPS.PA has a market cap of 2.7M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALBPS.PA trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALBPS.PA's P/E ratio is -0.03. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALBPS.PA's ROE of +1.88%. Regarding short-term risk, UCB.BR is less volatile compared to ALBPS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs GNRO.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, GNRO.PA has a market cap of 2.1M. Regarding current trading prices, UCB.BR is priced at €162.75, while GNRO.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas GNRO.PA's P/E ratio is -0.13. In terms of profitability, UCB.BR's ROE is +0.11%, compared to GNRO.PA's ROE of +2.39%. Regarding short-term risk, UCB.BR is less volatile compared to GNRO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALMDP.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALMDP.PA has a market cap of 1.8M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALMDP.PA trades at €0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALMDP.PA's P/E ratio is -0.59. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALMDP.PA's ROE of +0.40%. Regarding short-term risk, UCB.BR is less volatile compared to ALMDP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs BIOS.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, BIOS.BR has a market cap of 1.2M. Regarding current trading prices, UCB.BR is priced at €162.75, while BIOS.BR trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas BIOS.BR's P/E ratio is -0.04. In terms of profitability, UCB.BR's ROE is +0.11%, compared to BIOS.BR's ROE of +0.34%. Regarding short-term risk, UCB.BR is less volatile compared to BIOS.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALDEI.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALDEI.PA has a market cap of 1.1M. Regarding current trading prices, UCB.BR is priced at €162.75, while ALDEI.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALDEI.PA's P/E ratio is -0.11. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALDEI.PA's ROE of +0.61%. Regarding short-term risk, UCB.BR is less volatile compared to ALDEI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs OVXA.IR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, OVXA.IR has a market cap of 856.4K. Regarding current trading prices, UCB.BR is priced at €162.75, while OVXA.IR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas OVXA.IR's P/E ratio is -0.21. In terms of profitability, UCB.BR's ROE is +0.11%, compared to OVXA.IR's ROE of -0.00%. Regarding short-term risk, UCB.BR is more volatile compared to OVXA.IR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALNEV.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALNEV.PA has a market cap of 499.4K. Regarding current trading prices, UCB.BR is priced at €162.75, while ALNEV.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALNEV.PA's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALNEV.PA's ROE of -1.79%. Regarding short-term risk, UCB.BR is less volatile compared to ALNEV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs OXUR.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, OXUR.BR has a market cap of 290.4K. Regarding current trading prices, UCB.BR is priced at €162.75, while OXUR.BR trades at €0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas OXUR.BR's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.11%, compared to OXUR.BR's ROE of -0.01%. Regarding short-term risk, UCB.BR is less volatile compared to OXUR.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALPHA.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALPHA.PA has a market cap of 1.2K. Regarding current trading prices, UCB.BR is priced at €162.75, while ALPHA.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALPHA.PA's P/E ratio is -0.00. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALPHA.PA's ROE of +0.83%. Regarding short-term risk, UCB.BR is less volatile compared to ALPHA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs VLAP.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, VLAP.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while VLAP.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas VLAP.PA's P/E ratio is -0.10. In terms of profitability, UCB.BR's ROE is +0.11%, compared to VLAP.PA's ROE of -0.43%. Regarding short-term risk, UCB.BR is less volatile compared to VLAP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ASIT.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ASIT.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ASIT.BR trades at €0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ASIT.BR's P/E ratio is -32.71. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ASIT.BR's ROE of +0.38%. Regarding short-term risk, UCB.BR is less volatile compared to ASIT.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALNOX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALNOX.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ALNOX.PA trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALNOX.PA's P/E ratio is -0.19. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALNOX.PA's ROE of -2.36%. Regarding short-term risk, UCB.BR is less volatile compared to ALNOX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALIMM.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALIMM.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ALIMM.BR trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALIMM.BR's P/E ratio is -2.23. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALIMM.BR's ROE of -0.92%. Regarding short-term risk, UCB.BR is less volatile compared to ALIMM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ADVIC.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ADVIC.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ADVIC.PA trades at €6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ADVIC.PA's P/E ratio is -3.67. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ADVIC.PA's ROE of +0.44%. Regarding short-term risk, UCB.BR is less volatile compared to ADVIC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ACPH.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ACPH.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ACPH.BR trades at €0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ACPH.BR's P/E ratio is -1.40. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ACPH.BR's ROE of -1.55%. Regarding short-term risk, UCB.BR is more volatile compared to ACPH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs GKTX.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, GKTX.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while GKTX.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas GKTX.PA's P/E ratio is -2.56. In terms of profitability, UCB.BR's ROE is +0.11%, compared to GKTX.PA's ROE of -2.26%. Regarding short-term risk, UCB.BR is more volatile compared to GKTX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ALONC.PA Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ALONC.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ALONC.PA trades at €14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ALONC.PA's P/E ratio is 63.25. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ALONC.PA's ROE of -0.09%. Regarding short-term risk, UCB.BR is more volatile compared to ALONC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs BOTHE.BR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, BOTHE.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while BOTHE.BR trades at €0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas BOTHE.BR's P/E ratio is -0.38. In terms of profitability, UCB.BR's ROE is +0.11%, compared to BOTHE.BR's ROE of +7.51%. Regarding short-term risk, UCB.BR is less volatile compared to BOTHE.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.
UCB.BR vs ORPH.IR Comparison
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 30.9B. In comparison, ORPH.IR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €162.75, while ORPH.IR trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 30.31, whereas ORPH.IR's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.11%, compared to ORPH.IR's ROE of -0.00%. Regarding short-term risk, UCB.BR is more volatile compared to ORPH.IR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.